

**FORM 51 – 102F3**  
**MATERIAL CHANGE REPORT**

**1. Name and Address of Company**

bioMmune Technologies Inc.  
1780 – 400 Burrard Street  
Vancouver, BC V6C 3A6

**2. Date of Material Change**

November 18, 2015 and November 19, 2015

**3. News Release**

News releases dated November 18, 2015 and November 19, 2015 were disseminated through Marketwired and were filed via SEDAR on November 18, 2015 and November 19, 2015 respectively.

**4. Summary of the Material Change**

BioMmune Technologies Inc. Closes Non-Brokered Private Placement and Announces Appointment of Chief Scientific Officer.

**5. Full Description of the Material Change**

BioMmune Technologies Inc. (the “Company”) (TSX.V: IMU), is pleased to announce that it has closed the non-brokered private placement which was announced on October 11, 2015. The private placement is for 2,000,000 units (each a “Unit”) at a price of \$0.30 per Unit for gross proceeds of \$600,000. Each Unit consists of one common share and one common share purchase warrant (each a “Warrant”). Each Warrant entitles the holder to purchase one additional common share of the Company at a price of \$0.40 per share for a period of 24 months from the date of closing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company’s shares are trading at or above a volume weighted average price of \$0.60 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release.

The insiders of the Company purchased a total of 166,666 Units under the private placement and their participation in the Private Placement constitutes a "related party transaction" as defined in Multilateral Instrument 61-101 ("MI 61-101"). The Company relied on Section 5.5(a) of MI 61-101 for an exemption from the formal valuation requirement and Section 5.7(1)(a) of MI 61-101 for an exemption from the minority shareholder approval requirement of MI 61-101 as neither the fair market value of any shares issued to, or the consideration paid by such persons, exceeds 25% of the Company's market capitalization.

The proceeds from the sale of units will be added to working capital in furtherance of the Company’s business. No finders’ fee or commission was paid in connection with the private placement.

The securities issued under the placement are subject to a four-month hold period that expires on March 19, 2016. The private placement is subject to final acceptance by the TSX Venture Exchange upon filing of final documents.

BioMmune Technologies Inc. (“Biomune” or the “Company”) (TSX.V:IMU), a company focused on harnessing the body’s immune system to fight cancer and autoimmune diseases, is pleased to announce that it has appointed Patrick W. Gray, Ph.D. as Chief Scientific Officer, effective December 2, 2015.

In his role of Chief Scientific Officer, Dr. Gray will oversee the scientific operations of the Company.

Dr. Gray has spent 35 years in the biotechnology industry, focusing on drug discovery for critical diseases. He has a passion for working in small companies with aggressive timelines---Genentech, ICOS, MacroGenics, Nura and Accelerator were all less than 60 employees when he joined. Dr. Gray’s career accomplishments include the first cloning and characterization of Hepatitis B surface antigen, Interferon-gamma, multiple Interferon-alpha genes, Lymphotoxin (TNF-beta), Bactericidal Permeability Increasing Protein, LPS-Binding Protein, Platelet Activating Factor Acetylhydrolase, CCR5 (subsequently shown to be the HIV co-receptor), Macrophage Derived Chemokine, and PI3K p110-delta. These discoveries led to numerous clinical trials, several approved human pharmaceuticals, and characterization of targets for therapeutic monoclonal antibodies and small molecules. In addition to his scientific accomplishments, Dr. Gray previously held senior scientific management positions, including Vice President, Chief Scientific Officer, and CEO. Dr. Gray received his Ph.D. in chemistry from the University of Colorado and his B.S. in biology from the University of Oregon. He is currently an affiliate professor at the University of Washington.

CEO, Reinhard Gabathuler comments: *“Patrick Gray brings great experience in drug development from discovery to the clinic. We delighted to have him onboard leading our scientific team.”*

**6. Reliance on subsection 7.1(2) or (3) of National Instrument 51 – 102**

N/A

**7. Omitted Information**

N/A

**8. Executive Officer**

Dr. Reinhard Gabathuler, President  
Phone: (514) 963-6177

**9. Date of Report**

November 27, 2015